BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) 2018;10:E24. [PMID: 29361690 DOI: 10.3390/cancers10010024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Mylius CF, Krijnen WP, Takken T, Lips DJ, Eker H, van der Schans CP, Klaase JM. Objectively measured preoperative physical activity is associated with time to functional recovery after hepato-pancreato-biliary cancer surgery: a pilot study. Perioper Med (Lond) 2021;10:33. [PMID: 34602089 DOI: 10.1186/s13741-021-00202-7] [Reference Citation Analysis]
2 Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, Mccubrey JA. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation 2018;69:16-34. [DOI: 10.1016/j.jbior.2018.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin H, Libra M, Akula SM, Mccubrey JA. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation 2019;72:22-40. [DOI: 10.1016/j.jbior.2019.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Jiraskova L, Ryska A, Duintjer Tebbens EJ, Hornychova H, Cecka F, Staud F, Cerveny L. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers (Basel) 2019;11:E1621. [PMID: 31652721 DOI: 10.3390/cancers11111621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aziz H, Zeeshan M, Jie T, Maegawa FB. Neoadjuvant Chemoradiation Therapy is Associated with Adverse Outcomes in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Cancer. The American Surgeon 2019;85:1276-80. [DOI: 10.1177/000313481908501136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fitzgerald TL, Hunter L, Mosquera C, Jindal C, Biswas T, Zervos E, Efird JT. A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy. HPB (Oxford) 2019;21:204-11. [PMID: 30087052 DOI: 10.1016/j.hpb.2018.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Tella SH, Kommalapati A, Yadav S, Bergquist JR, Goyal G, Durgin L, Borad M, Cleary SP, Truty MJ, Mahipal A. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol 2020;46:789-95. [PMID: 31954549 DOI: 10.1016/j.ejso.2020.01.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, Weiss MJ, Wolfgang C, He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. J Gastrointest Surg 2019;23:112-21. [PMID: 30242644 DOI: 10.1007/s11605-018-3966-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
9 Li X, Li S, Liu L, Hong J, Zhao T, Gao C. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. J Cancer 2020;11:9-15. [PMID: 31892968 DOI: 10.7150/jca.33767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pei X, Song F, Wang Z. Emerging incidence trends and application of curative treatments of pancreatic cancer in the USA. Medicine (Baltimore) 2019;98:e17175. [PMID: 31860944 DOI: 10.1097/MD.0000000000017175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Malatesta L, Cosco D, Paolino D, Cilurzo F, Costa N, Di Tullio A, Fresta M, Celia C, Di Marzio L, Locatelli M. Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride in rat plasma by using high performance liquid chromatography-diode array detector. J Pharm Biomed Anal 2018;159:192-9. [PMID: 29990886 DOI: 10.1016/j.jpba.2018.06.060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
12 Wiest NE, Moktan VP, Oman SP, Chirilă RM. Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 2020;58:119-28. [PMID: 32364522 DOI: 10.2478/rjim-2020-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 He C, Sun S, Zhang Y, Li S. Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irreversible Electroporation. J Inflamm Res 2021;14:1689-99. [PMID: 33953596 DOI: 10.2147/JIR.S307884] [Reference Citation Analysis]
14 Zhang C, Ding J, Xu X, Liu Y, Huang W, Da L, Ma Q, Chen S. Tumor Microenvironment Characteristics of Pancreatic Cancer to Determine Prognosis and Immune-Related Gene Signatures. Front Mol Biosci 2021;8:645024. [PMID: 34169093 DOI: 10.3389/fmolb.2021.645024] [Reference Citation Analysis]
15 Roa-Peña L, Babu S, Leiton CV, Wu M, Taboada S, Akalin A, Buscaglia J, Escobar-Hoyos LF, Shroyer KR. Keratin 17 testing in pancreatic cancer needle aspiration biopsies predicts survival. Cancer Cytopathol 2021. [PMID: 34076963 DOI: 10.1002/cncy.22438] [Reference Citation Analysis]
16 Abrams SL, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Libra M, Falzone L, Candido S, Montalto G, Cervello M, Lombardi P, McCubrey JA. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Adv Biol Regul 2021;:100840. [PMID: 34866036 DOI: 10.1016/j.jbior.2021.100840] [Reference Citation Analysis]
17 Ungureanu BS, Pirici D, Dima SO, Popescu I, Hundorfean G, Surlin V, Saftoiu A. Morphometric Assessment of Confocal Laser Endomicroscopy for Pancreatic Ductal Adenocarcinoma, an Ex-Vivo Pilot Study. Diagnostics (Basel) 2020;10:E923. [PMID: 33182544 DOI: 10.3390/diagnostics10110923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Fernandez Y Viesca M, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. Clin Exp Gastroenterol. 2019;12:415-432. [PMID: 31807048 DOI: 10.2147/ceg.s195714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
19 Abrams SL, Akula SM, Martelli AM, Cocco L, Ratti S, Libra M, Candido S, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS, McCubrey JA. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Adv Biol Regul 2021;79:100780. [PMID: 33451973 DOI: 10.1016/j.jbior.2020.100780] [Reference Citation Analysis]
20 Ren L, Mota Reyes C, Friess H, Demir IE. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? Langenbecks Arch Surg 2020;405:879-87. [PMID: 32776259 DOI: 10.1007/s00423-020-01946-4] [Reference Citation Analysis]
21 Taylor RJ, Todor D, Kaplan BJ, Stover W, Fields EC. CivaSheet intraoperative radiation therapy for pancreatic cancer. Brachytherapy 2022. [DOI: 10.1016/j.brachy.2021.10.007] [Reference Citation Analysis]
22 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zhao J, Schlößer HA, Wang Z, Qin J, Li J, Popp F, Popp MC, Alakus H, Chon SH, Hansen HP, Neiss WF, Jauch KW, Bruns CJ, Zhao Y. Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Cancers (Basel) 2019;11:E874. [PMID: 31234517 DOI: 10.3390/cancers11060874] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
24 Liu D, Song L, Dai Z, Guan H, Kang H, Zhang Y, Yan W, Zhao X, Zhang S. MiR-429 suppresses neurotrophin-3 to alleviate perineural invasion of pancreatic cancer. Biochem Biophys Res Commun 2018;505:1077-83. [PMID: 30314698 DOI: 10.1016/j.bbrc.2018.09.147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
25 Li S, Zhang G, Li X, Li X, Chen X, Xu Y, Ren H. Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer. Pharmacogenomics 2021;22:657-67. [PMID: 34120460 DOI: 10.2217/pgs-2020-0183] [Reference Citation Analysis]
26 Gagliano T, Brancolini C. Epigenetic Mechanisms beyond Tumour-Stroma Crosstalk. Cancers (Basel) 2021;13:914. [PMID: 33671588 DOI: 10.3390/cancers13040914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
27 Saccomandi P, Lapergola A, Longo F, Schena E, Quero G. Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. Int J Hyperthermia. 2018;35:398-418. [PMID: 30428728 DOI: 10.1080/02656736.2018.1506165] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
28 Yu J, Li Q, Zhang H, Meng Y, Liu YF, Jiang H, Ma C, Liu F, Fang X, Li J, Feng X, Shao C, Bian Y, Lu J. Contrast-enhanced computed tomography radiomics and multilayer perceptron network classifier: an approach for predicting CD20+ B cells in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY) 2021. [PMID: 34708252 DOI: 10.1007/s00261-021-03285-4] [Reference Citation Analysis]
29 Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Mol Oncol 2020;14:1800-16. [PMID: 32533886 DOI: 10.1002/1878-0261.12743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]